Replies to post #150636 on Biotech Values

[DewDiligence]

Why not treat patients initially with a nuke-based combo? If that fails try another or throw the basket at them (ABT).

I think you want to start with the regimen that has the highest SVR for the patient type unless there are two or more options that are close. To start with a regimen that is sub-optimal in SVR by more than 8-10 percentage points would require an extraordinarily persuasive argument, IMO.